SpIntellx and CellNetix Collaborate to Validate HistoMapr-Breast™, an Explainable AI Software Platform Featuring Advanced Spatial Analytics to Provide Intelligent Guides for Pathology Laboratories
Pittsburgh, PA, July 7, 2020 – SpIntellx, Inc., and CellNetix Pathology & Laboratories have announced that they will collaborate to validate the SpIntellx HistoMapr-Breast™ Platform, which taps the power of explainable artificial intelligence (xAI) for healthcare providers to diagnose and treat breast cancer more efficiently and accurately. The platform is the first in the companies’ larger efforts to harness the power of xAI-assisted lab processes in the development of diagnostics, prognostics, therapeutic strategies, and drug development for tumor and non-tumor diseases.
SpIntellx, Inc. is a computational and systems pathology company that harnesses the computational power of unbiased spatial analytics and explainable artificial intelligence (xAI) technologies to offer proprietary software products and services for analyzing pathology tissue sections. CellNetix Pathology & Laboratories is a rapidly growing pathology laboratory company providing comprehensive subspecialty clinical and anatomic pathology services in the Pacific Northwest.
SpIntellx brings a proprietary spatial analytics approach to digital pathology. The advanced spatial analytics capture the architecture and communication patterns of the various histological structures, thus yielding maximally predictive information from patients’ tissue sections to inform therapeutic strategies and clinical decisions. HistoMapr-Breast uses this information to provide clear and unbiased justifications for its automated recommendations. As a result, pathologists and other software users can ask “why?” and HistoMapr-Breast can answer this basic question, using data to explain its decisions. This is a vital feature in building trust and transparency between pathology disease experts and computational pathology systems, and it is also a departure from more traditional black-box AI approaches to digital pathology such as deep learning. As machine learning accelerates in medicine, improved communication between humans and their machine learning tools is critical.
HistoMapr-Breast is the first of many planned spatial analytics and xAI pathologist guides designed to: triage the case workload to direct the most difficult and borderline cases to subspecialists; perform retroactive quality assurance to improve pathologists’ accuracy and efficiency and reduce intra- and inter-pathologist discordance; provide transparent xAI guidance that explains why the algorithms made a specific recommendation; and facilitate standardized reporting in real time. The HistoMapr technology and approach is generalizable to a wide range of diseases, both tumor and non-tumor in nature.
“We are thrilled to be working with SpIntellx in further developing and validating HistoMapr and the use of explainable artificial intelligence (xAI) in the practice of pathology,” remarked Dr. Dominique Coco, lead project pathologist with CellNetix Pathology & Laboratories. “We see great potential in xAI which could rapidly reshape how we practice pathology.”
“We will be working closely with CellNetix Pathology & Laboratories to complete the validation of HistoMapr-Breast as the final step in our commercialization process. We are delighted to be partnering with the experts at CellNetix in the next step toward revolutionizing the impact of pathology on precision medicine,” stated SpIntellx co-founder and CEO, S. Chakra Chennubhotla, PhD.
About SpIntellx:
SpIntellx, Inc., based in Pittsburgh, PA, USA, is a pioneer in offering proprietary spatial analytics and xAI-focused software platforms and services, HistoMapr™ and TumorMapr™, for the rapidly emerging field of computational and systems pathology that is projected to revolutionize the application of pathology in prognostics and diagnostics, drug target identification, patient stratification for clinical trials, and generation of personalized therapeutic strategies, while improving the efficiency and accuracy in the practice of pathology. The HistoMapr™ platform covers transmitted light applications, and TumorMapr™ platform covers multiplexed to hyperplexed fluorescence and mass spec-based labeling and imaging applications. The company’s products can be used individually or in combination, and have the ability to analyze image data from any imaging platform harnessing any reagent type. For more information, visit: www.spintellx.com.
About CellNetix Pathology & Laboratories:
CellNetix Pathology & Laboratories is a private pathology company with 60+ board-certified pathologists serving hospitals and clinics throughout the Pacific Northwest for more than 50 years. With more than 25 subspecialties and a dedicated team of 300 technicians and professionals, it offers one of the largest and most comprehensive anatomic and molecular pathology service menus in the region. For more information, visit www.cellnetix.com.
